prikaz prve stranice dokumenta The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study
  Download
PDF 189.6 KB
Scientific paper - Original scientific paper
The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study
Croatian Medical Journal, 61 (2020), 2; 93-99. https://doi.org/10.3325/cmj.2020.61.93
Bukvić Mokos, Zrinka; Petković, Mikela; Balić, Anamaria; Marinović, Branka

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Bukvić Mokos, Z., Petković, M., Balić, A. & Marinović, B. (2020). The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study. Croatian Medical Journal, 61. (2), 93-99. doi: 10.3325/cmj.2020.61.93

Bukvić Mokos, Zrinka, et al. "The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study." Croatian Medical Journal, vol. 61, no. 2, 2020, pp. 93-99. https://doi.org/10.3325/cmj.2020.61.93

Bukvić Mokos, Zrinka, Mikela Petković, Anamaria Balić and Branka Marinović. "The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study." Croatian Medical Journal 61, no. 2 (2020): 93-99. https://doi.org/10.3325/cmj.2020.61.93

Bukvić Mokos, Z., et al. (2020) 'The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study', Croatian Medical Journal, 61(2), pp. 93-99. doi: 10.3325/cmj.2020.61.93

Bukvić Mokos Z, Petković M, Balić A, Marinović B. The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study. Croatian Medical Journal [Internet]. 2020 April 30 [cited 2024 December 25];61(2):93-99. doi: 10.3325/cmj.2020.61.93

Z. Bukvić Mokos, M. Petković, A. Balić and B. Marinović, "The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study", Croatian Medical Journal, vol. 61, no. 2, pp. 93-99, April 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:598782. [Accessed: 25 December 2024]

Metadata
Title (english)The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study
AuthorZrinka Bukvić Mokos
MBZ: 279423
AuthorMikela Petković
AuthorAnamaria Balić
AuthorBranka Marinović
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Dermatology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Dermatovenerology
Abstract (english)
Aim: To evaluate the association between the use of dipeptidyl peptidase-4 inhibitors (DPP4I) and clinical and laboratory findings of bullous pemphigoid (BP) in patients treated at the European Reference Network - Skin Reference Centre in Croatia. ----- Methods: This retrospective study enrolled 82 patients treated for BP at the Department of Dermatovenereology, University Hospital Center Zagreb from January 2015 to December 2019. Clinical features of BP, presence of comorbidities, and laboratory findings of anti-BP antibodies and eosinophilia were analyzed in three groups of BP patients: 1) diabetes mellitus (DM) type II patients treated with DPP4I, 2) DM type II patients not treated with DPP4I, and 3) non-DM type II patients. ----- Results: The average age and anti-BP180 titer were similar in all three groups. DPP4I group had a slightly lower eosinophil level in both peripheral blood (4.89%) and biopsy specimens (87.5%), but the difference was not significant. The prevalence of inflammatory BP in DPP4I group was 76.5%. DPP4I group had significantly higher percentage of patients with chronic renal failure and dementia (52.9% and 11.8%, respectively) compared with non-DPP4I DM (14.3% and 0%, respectively) and non-DM type II patients (15.7% and 0%, respectively). ----- Conclusion: BP patients treated with DPP4I and those not treated with DPP4Is did not significantly differ in laboratory findings. However, DPP4I treatment was associated with an inflammatory subtype of BP and a higher prevalence of dementia and chronic renal failure. These findings warrant further research into the association of BP and DM with dementia and chronic renal failure.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCroatian Medical Journal
Numberingvol. 61, no. 2, pp. 93-99
p-ISSN0353-9504
e-ISSN1332-8166
DOIhttps://doi.org/10.3325/cmj.2020.61.93
URN:NBNurn:nbn:hr:105:598782
Publication2020-04-30
Document URLhttp://www.cmj.hr/2020/61/2/32378375.htm
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2020-10-27 12:49:01